Reduced intensity haploidentical transplantation with NK [natural killer] cell infusion for pediatric acute leukemia and high risk solid tumors, BMT06407.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antithymocyte globulin; Ciclosporin; Fludarabine; Melphalan; Methylprednisolone; Muromonab CD3; Rituximab; Thiotepa
- Indications Graft-versus-host disease; Leukaemia; Solid tumours
- Focus Therapeutic Use
- 09 Dec 2019 Biomarkers information updated
- 22 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 24 May 2011 Planned End Date changed from 1 Feb 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.